Striatal and Extrastriatal D2/D3-Receptor-Binding Properties of Ziprasidone: A Positron Emission Tomography Study With [18F]Fallypride and [11C]Raclopride (D2/D3-Receptor Occupancy of Ziprasidone)

To elucidate the "atypicality" of ziprasidone, its striatal and extrastriatal D2/D3-receptor binding was characterized in patients with schizophrenia under steady-state conditions. These data were compared with striatal receptor occupancy values after single-dose ziprasidone ingestion in healthy controls. [18F]fallypride positron emission tomography (PET) recordings were obtained in 15 patients under steady-state ziprasidone treatment at varying time points after the last dose. Binding potentials were calculated for striatal and extrastriatal regions. D2/D3-receptor occupancies were expressed relative to binding potentials in 8 unmedicated patients. In a parallel [11C]raclopride-PET study, striatal D2/D3-receptor occupancy was measured in healthy subjects after single oral doses of 40 mg ziprasidone or 7.5 mg haloperidol. Ziprasidone plasma concentrations correlated significantly with D2/D3-receptor occupancies in all volumes of interests. Occupancy in extrastriatal regions was approximately 10% higher than in striatal regions. Half maximal effective concentration values were consistently higher in striatal than in extrastriatal regions (temporal cortex: 39 ng/mL; putamen: 64 ng/mL), irrespective of the time between last dosing and scan. Single ziprasidone doses resulted in higher occupancies exceeding the 95% prediction limits of the occupancy versus plasma concentrations for chronic dosing. Ziprasidone shares moderate preferential extrastriatal D2/D3-receptor binding with some other atypicals. D2/D3-receptor occupancy is rapidly attuning to the daily course of ziprasidone plasma levels, suggesting relatively high intraday variations of D2/D3-receptor binding. The discrepancies between single-dose and steady-state results are important for the future design of dose-finding PET occupancy studies of novel antipsychotics. Single-dose studies may not be totally relied on for final dose selection.

[1]  Lars H. Pinborg,et al.  [123I]Epidepride binding to cerebellar dopamine D2/D3 receptors is displaceable: Implications for the use of cerebellum as a reference region , 2007, NeuroImage.

[2]  S. Woods,et al.  Chlorpromazine equivalent doses for the newer atypical antipsychotics. , 2003, The Journal of clinical psychiatry.

[3]  Phil Jeffrey,et al.  Central Nervous System Drug Disposition: The Relationship between in Situ Brain Permeability and Brain Free Fraction , 2007, Journal of Pharmacology and Experimental Therapeutics.

[4]  Hans-Georg Buchholz,et al.  The Striatal and Extrastriatal D2/D3 Receptor-Binding Profile of Clozapine in Patients with Schizophrenia , 2006, Neuropsychopharmacology.

[5]  Paul Cumming,et al.  Parametric mapping of binding in human brain of D2 receptor ligands of different affinities. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  C. Halldin,et al.  No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457. , 2001, The American journal of psychiatry.

[7]  S. Kapur,et al.  Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. , 1999, The American journal of psychiatry.

[8]  Jogeshwar Mukherjee,et al.  Evaluation of Dopamine D-2 Receptor Occupancy by Clozapine, Risperidone, and Haloperidol In Vivo in the Rodent and Nonhuman Primate Brain Using 18F-Fallypride , 2001, Neuropsychopharmacology.

[9]  S. Kapur,et al.  A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. , 2000, Archives of general psychiatry.

[10]  Markus Piel,et al.  Quantification of D 2-Like Dopamine Receptors in the Human Brain with 18 F-Desmethoxyfallypride , 2002 .

[11]  P. Weiden,et al.  Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. , 2004, The American journal of psychiatry.

[12]  Christer Halldin,et al.  5-HT2 and D2 dopamine receptor occupancy in the living human brain , 1993, Psychopharmacology.

[13]  S. Potkin,et al.  Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder: A 6-Week Placebo-Controlled Trial , 1999, Neuropsychopharmacology.

[14]  Gerhard Gründer,et al.  Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597): A Study Using Positron Emission Tomography and [11C]Raclopride , 2002, Neuropsychopharmacology.

[15]  D. Wong,et al.  Erratum: Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597): A Study Using Positron Emission Tomography and [11C]Raclopride⋆ , 2002, Neuropsychopharmacology.

[16]  Hans-Georg Buchholz,et al.  High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. , 2004, The international journal of neuropsychopharmacology.

[17]  Christoph Hiemke,et al.  Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. , 2008, The American journal of psychiatry.

[18]  R. Dolan,et al.  The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography , 1996, Psychopharmacology.

[19]  S. Kapur,et al.  A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. , 2004, The American journal of psychiatry.

[20]  Markus Piel,et al.  In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D(2)-like dopamine receptors. , 2007, Bioorganic & medicinal chemistry.

[21]  Alan A. Wilson,et al.  Striatal Vs Extrastriatal Dopamine D2 Receptors in Antipsychotic Response—A Double-Blind PET Study in Schizophrenia , 2007, Neuropsychopharmacology.

[22]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[23]  Peter J Ell,et al.  Limbic selectivity of clozapine , 1997, The Lancet.

[24]  J Tauscher,et al.  Significant dissociation of brain and plasma kinetics with antipsychotics , 2002, Molecular Psychiatry.

[25]  C. Halldin,et al.  A PET Study of 5-HT2 and D2 Dopamine Receptor Occupancy Induced by Olanzapine in Healthy Subjects , 1997, Neuropsychopharmacology.

[26]  N. Alpert,et al.  Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. , 1996, The Journal of pharmacology and experimental therapeutics.

[27]  S. Potkin,et al.  Ziprasidone in Acute Bipolar Mania: A 21-Day Randomized, Double-Blind, Placebo-Controlled Replication Trial , 2005, Journal of clinical psychopharmacology.

[28]  C. Hiemke,et al.  Automated Determination of Ziprasidone by HPLC With Column Switching and Spectrophotometric Detection , 2005, Therapeutic drug monitoring.

[29]  Markus Piel,et al.  Quantification of D2-like dopamine receptors in the human brain with 18F-desmethoxyfallypride. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  Mohammad Sib Ansari,et al.  Occupancy of Striatal and Extrastriatal Dopamine D2/D3 Receptors by Olanzapine and Haloperidol , 2005, Neuropsychopharmacology.

[31]  Alan A. Wilson,et al.  5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. , 1998, The American journal of psychiatry.

[32]  T Greitz,et al.  Preparation of 11C-labelled Raclopride, a new potent dopamine receptor antagonist: preliminary PET studies of cerebral dopamine receptors in the monkey. , 1985, The International journal of applied radiation and isotopes.

[33]  Lars Farde,et al.  Potentials and Pitfalls Using High Affinity Radioligands in PET and SPET Determinations on Regional Drug Induced D2 Receptor Occupancy—A Simulation Study Based on Experimental Data , 2001, NeuroImage.

[34]  Christer Halldin,et al.  A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients , 1997, Psychopharmacology.

[35]  Alan A. Wilson,et al.  Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study , 2000, Psychopharmacology.

[36]  Christer Halldin,et al.  Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients , 1993, Biological Psychiatry.

[37]  G. Frankle.  Neuroreceptor Imaging Studies in Schizophrenia , 2007, Harvard review of psychiatry.

[38]  R. Blakely,et al.  Pharmacological profile of neuroleptics at human monoamine transporters. , 1999, European journal of pharmacology.

[39]  E. Richelson,et al.  Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. , 2000, Life sciences.

[40]  L. Mallet,et al.  Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia , 2001, British Journal of Psychiatry.

[41]  Hans-Georg Buchholz,et al.  Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge , 2006, NeuroImage.

[42]  J. Feighner,et al.  Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial , 1998, Psychopharmacology.

[43]  M. Jann,et al.  Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients , 1989, Biological Psychiatry.

[44]  M. Tegner,et al.  Antischizophrenic Drugs : Chronic Treatment Elevates Dopamine Receptor Binding in Brain , 2006 .

[45]  D. Puigdemont,et al.  Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[46]  S. Gacinovic,et al.  Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study , 2000, Psychopharmacology.

[47]  R. S. J. Frackowiak,et al.  Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and11C-raclopride , 2005, Psychopharmacology.

[48]  S. Kapur,et al.  Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels , 2000, Psychopharmacology.

[49]  Gitte Moos Knudsen,et al.  [123I]epidepride binding to cerebellar dopamine D2/D3 receptors is displaceable: Implications for the use of cerebellum as a reference region , 2006, NeuroImage.

[50]  Benoit Dawant,et al.  Occupancy of Striatal and Extrastriatal Dopamine D2 Receptors by Clozapine and Quetiapine , 2006, Neuropsychopharmacology.

[51]  Mark Slifstein,et al.  Dose–Occupancy Study of Striatal and Extrastriatal Dopamine D2 Receptors by Aripiprazole in Schizophrenia with PET and [18F]Fallypride , 2008, Neuropsychopharmacology.

[52]  Alan A. Wilson,et al.  The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. , 1995, Life sciences.

[53]  S. Hirsch,et al.  A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia , 1999, European Neuropsychopharmacology.

[54]  D. Goff,et al.  An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. , 1998, Journal of clinical psychopharmacology.

[55]  B Müller-Oerlinghausen,et al.  The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry , 2004, Pharmacopsychiatry.

[56]  K. Erlandsson,et al.  Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. , 2003, The American journal of psychiatry.

[57]  T. Tensfeldt,et al.  Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. , 2000, British journal of clinical pharmacology.